[ET Net News Agency, 23 August 2021] WuXi Biologics (Cayman) Inc. (02269) said its net
profit attributable to owners of the company was RMB1,842.1 million for the six months
ended 30 June 2021, a year-on-year increase of 150.3%. Basic earnings per share were
RMB0.44. No dividend will be distributed.
Revenue was RMB4,406.8 million, a year-on-year increase of 126.7%. (RC)